argenx SE (ARGX) Stock Analysis
Verdict: BUY
Sanofi's trial failure eliminates a primary competitor, de-risking Vyvgart's $7B+ peak sales trajectory in the CIDP market.
Investment score: 74/100
Analysis as of
Is argenx SE stock worth reviewing? The TradeMates thesis
argenx is entering a 'virtuous cycle' of profitability fueled by Vyvgart's expansion. Recent peer failures in CIDP solidify its market leadership.
7-factor investment score
- Valuation: 60/100 (weight 20%)
- Financial Health: 85/100 (weight 15%)
- Technical Momentum: 78/100 (weight 15%)
- Earnings Quality: 90/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 88/100 (weight 10%)
- Risk-Adjusted Return: 65/100 (weight 15%)
argenx SE opportunities and risks
What speaks for ARGX
- Competitive Clearance in CIDP Indication
What speaks against ARGX
- Payer Reimbursement Pressures
Peers and competitors
- ARGX.BR
- NAMS
- QURE
- PHARM.AS
- PRQR
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ARGX | 48.9x | 16.4x | 54.0x | 89.0% | 33.4% | 1.3% |
| NAMS | n/a | 156.8x | n/a | 97.5% | -942.8% | -4.0% |
| QURE | n/a | 93.5x | n/a | 74.1% | -1154.4% | -10.2% |
| PRQR | n/a | 9.7x | n/a | 89.7% | -339.4% | -37.4% |
| Peer median | n/a | 93.5x | n/a | 89.7% | -942.8% | -10.2% |
Frequently asked questions about argenx SE (ARGX)
Is ARGX stock a good investment?
The TradeMates model rates argenx SE as BUY with an investment score of 74/100. argenx is entering a 'virtuous cycle' of profitability fueled by Vyvgart's expansion. Recent peer failures in CIDP solidify its market leadership. This is algorithmic model output, not personal investment advice.
Is ARGX stock a buy?
The TradeMates model verdict for ARGX is BUY with an investment score of 74/100. Treat this as a model signal to review, not a personal buy recommendation.